The tumor-reactiveT cells then migrate to the tumor site and eliminate cancer cellsthrough mechanisms such as cytokine release and cytotoxic effects.9 However, inadequate secretion of ATP and HMGB1is often observed with cells killed by radiotherapy and chemotherapy.10,11 Exogenous administration of DAMPs, including ATP and CRT,12−14 has been shown to modulate the TME and enhance antitumor immunity.Although intriguing, these approaches have not been widely adopted,likely due to challenges such as poor targeting, rapid clearance,and unwanted toxicity. The gene discussed is CALR; the disease is neoplasm.